To include your compound in the COVID-19 Resource Center, submit it here.

Mepolizumab: Additional Phase III data

Additional data from the double-blind, international Phase III MEA115588 (MENSA) trial in 576 patients showed that 100 mg subcutaneous mepolizumab given every 4 weeks for 32 weeks met the secondary endpoint of reducing the frequency of clinically significant

Read the full 380 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers